Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings season.

GEHC vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre’s second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and Asia. However, the quarter fell short of Wall Street’s revenue and profit expectations, which contributed to a negative market reaction. Management attributed the underperformance to a combination of adverse currency impacts, ongoing Middle East export delays, and supply constraints in cardiac allografts. CEO George LeMaitre highlighted that,

Artegraft sales surged 34% as gross margins expanded to 72.1%.

What the latest earnings and guidance mean for LeMaitre Vascular stock LeMaitre Vascular (LMAT) has attracted fresh attention after reporting second quarter 2026 results that included higher sales and net income, alongside new earnings guidance and an affirmed quarterly dividend. For the second quarter ended June 30, 2026, LeMaitre Vascular reported sales of US$70.38 million compared with US$64.23 million a year earlier. Net income was US$17.05 million compared with US$13.78 million in the...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm […]

Moby summary of LeMaitre Vascular, Inc.'s Q2 2026 earnings call

LeMaitre Vascular Inc (LMAT) reports 10% organic sales growth and 23% EPS growth in Q2 2026, driven by Artegraft and margin expansion, despite FX headwinds and supply challenges.

LeMaitre Vascular (NASDAQ:LMAT) reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign exchange, Middle East export delays and cardiac allograft supply constraints weighed on sales relati

LeMaitre (LMAT) delivered earnings and revenue surprises of -8.64% and -1.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 million. Next quarter’s revenue guidance of $67.3 million underwhelmed, coming in 3% below analysts’ estimates. Its GAAP profit of $0.74 per share was 8.3% below analysts’ consensus estimates.

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Tuesday after market close. Here’s what you need to know.